CIPLA CHART IN 1D TF.
ANALYSIS:
RSI DIVERGENCE (BULLISH) Formed.
Case-1:
As per Technical Indicator if it breaks Trend Line Can go for Long above 432.55 and can see an upward Movement
Case-2:
If it breaks Support go or short below 419.2 and we can see downfall Movement.
CIPLA CHART IN 1D TF.
Note:
Orange Line-> Trend Line
Black Line -> RSI Divergence
Blue Line -> Channel
ANALYSIS:
RSI DIVERGENCE (BULLISH) Formed.
Case-1:
As per Technical Indicator if it breaks Trend Line Can go for Long above 432.55 and can see an upward Movement
Case-2:
If it breaks Support go or short below 419.2 and we can see downfall Movement.
cipla has broken trend line on weekly chart
big candle channel is developed
stock taken support on 200 ema
buy this counter with sl of 570 on closing basis
target 616 then 655
enjoy
It is been observed on the Weekly and Daily chart that the price action is breaking out from a downward channel as well as from pitchfork lines, indicating a further move up.
Target: 600
Stoploss: 578
Cipla Daily Chart is interesting. Can you Analyze and predict what may happen?
Clue lies on the left of the chart. Look at the Left. Previous setup gives an indication of what is going to happen however that does not mean that what has happened in past will repeat again. I want you guys to analyze and predict. This will enhance your skills and will give you...
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
CIPLA
